» Articles » PMID: 17576300

Association of Mineral Metabolism Factors with All-cause and Cardiovascular Mortality in Hemodialysis Patients: the Japan Dialysis Outcomes and Practice Patterns Study

Overview
Journal Hemodial Int
Date 2007 Jun 20
PMID 17576300
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Abnormalities in mineral metabolism have been linked to mortality in hemodialysis (HD) patients. We postulated that these abnormalities would have a particularly large deleterious impact on deaths due to cardiovascular causes in Japan. This study describes the recent status of abnormal mineral metabolism, significant predictors, and potential consequences in the Dialysis Outcomes and Practice Patterns Study (DOPPS), Phases 1 and 2, in Japan. Major predictor variables were patient demographics, comorbidities, and laboratory markers of mineral metabolism such as albumin-adjusted serum calcium (calciumAlb), phosphorus, and intact PTH (iPTH). In a cross section of 3973 Japanese HD patients in DOPPS I and II, a large faction had laboratory values outside of the recommended Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline range for serum concentrations of phosphorus (51% of patients above upper target range), calciumAlb (43.7% above), calcium-phosphorus (Ca x P) product (41.1% above), and iPTH (18.6% above). All-cause mortality was significantly and independently associated with calciumAlb (relative risk [RR]=1.22 per 1 mg/dL, p=0.0005) and iPTH (RR=1.04 per 100 pg/mL, p=0.04). Cardiovascular mortality was significantly associated with calciumAlb (RR=1.28, p=0.02), phosphorus (RR=1.13 per 1 mg/dL, p=0.008), Ca x P product (RR=1.07 per 2 mg(2)/dL(2), p=0.002), and PTH (RR=1.08, p=0.0001). This study expands our understanding of the relationship between altered mineral metabolism and mortality outcomes, showing slightly stronger associations with cardiovascular causes than observed for all-cause mortality. These findings have important therapeutic implications for Japanese HD patients.

Citing Articles

The effects of dialysate calcium prescription on mortality outcomes in incident patients on hemodialysis.

Ter Meulen K, Carioni P, Bellocchio F, van der Sande F, Bouman H, Stuard S Clin Kidney J. 2024; 17(10):sfae288.

PMID: 39385946 PMC: 11462444. DOI: 10.1093/ckj/sfae288.


Coronary Artery Disease in Patients Undergoing Hemodialysis: A Problem that Sounds the Alarm.

Barbuto S, Hu L, Abenavoli C, Picotti M, La Manna G, De Nicola L Rev Cardiovasc Med. 2024; 25(6):200.

PMID: 39076335 PMC: 11270123. DOI: 10.31083/j.rcm2506200.


Longer serum phosphorus time in range associated with lower mortality risk among peritoneal dialysis patients: a multicenter retrospective cohort study.

Huo Z, Liu D, Ye P, Zhang Y, Cao L, Gong N BMC Nephrol. 2024; 25(1):117.

PMID: 38553732 PMC: 10981292. DOI: 10.1186/s12882-023-03395-9.


Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia.

Nitta K, Itoyama S, Ikejiri K, Kinoshita J, Nakanishi K, Fukagawa M Kidney Int Rep. 2023; 8(11):2243-2253.

PMID: 38025211 PMC: 10658421. DOI: 10.1016/j.ekir.2023.08.003.


Associations of calcium, phosphate and intact parathyroid hormone levels with mortality, residual kidney function and technical failure among patients on peritoneal dialysis.

Murashima M, Fujii N, Goto S, Hasegawa T, Abe M, Hanafusa N Clin Kidney J. 2023; 16(11):1957-1964.

PMID: 37915934 PMC: 10616493. DOI: 10.1093/ckj/sfad223.